Form 4 for RPRX Royalty Pharma plc
Accepted 2025-05-09 00:00:00 ET · period of report 2025-05-08 · accession 0001802768-25-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-09 | 2025-05-08 | RPRX | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +36.5K | 83.2K | +78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2025-05-08 | A | A | 36,484 | $0.00 | 83,151 | D | — | — | (F1) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. |